Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774436 | 0.83 | SLC5A2 (0.34) | SLC5A2TACR2SSTR4PTPN1 | |
| SCHEMBL12425872 | 0.80 | SLC5A2 (0.48) | SLC5A2TACR2SSTR4PTPN1SSTR1 | |
| SCHEMBL1774673 | 0.79 | SLC5A2 (0.34) | SLC5A2TACR2 | |
| SCHEMBL1775979 | 0.79 | TACR2 (0.34) | TACR2SSTR4SSTR1SSTR2SSTR3 | |
| SCHEMBL1775976 | 0.78 | CLK1 (0.37) | SLC5A2TACR2SSTR4PTPN1SSTR1 | |
| SCHEMBL5270077 | 0.78 | TACR2 (0.35) | SLC5A2TACR2PTPN1 | |
| SCHEMBL5270081 | 0.78 | TACR2 (0.35) | SLC5A2TACR2PTPN1 | |
| SCHEMBL20741941 | 0.77 | SLC5A2 (0.37) | SLC5A2 | |
| SCHEMBL20139462 | 0.77 | PTPN1 (0.34) | SLC5A2TACR2PTPN1 | |
| SCHEMBL1775301 | 0.76 | TP53 (0.32) | SLC5A2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885TACR2 1041/4885SSTR4 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.